November 7, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Impax Laboratories Inc (NASDAQ:IPXL) shares over potential securities laws violations by Impax Laboratories and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Impax Laboratories Inc (NASDAQ:IPXL) concerning whether a series of statements by Impax Laboratories regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Impax Laboratories Inc reported that its annual Total Revenue rose from $596.05 million in 2014 to $860.47 million in 2015 and that its Net Income declined from $57.35 million in 2014 to $39.00 million in 2015.

On November 3, 2016, media outlets reported that United States prosecutors may file criminal charges by the end of 2016 against Impax Laboratories Inc and several other pharmaceutical companies for unlawfully colluding to fix generic drug prices.

Shares of Impax Laboratories Inc (NASDAQ:IPXL) declined from as high as $50.42 per share in July 2015 to as low as $16.40 per share on November 3, 2016.

On November 7, 2016, NASDAQ:IPXL shares closed at $17.85 per share.